CranioSense

Executive Summary

CranioSense is a privately held medical device company headquartered in San Francisco, founded in 2019, that is developing a non-invasive system for measuring intracranial pressure (ICP) called IPASS. Current ICP monitoring requires invasive brain surgery, limiting use to severe cases and delaying timely intervention. CranioSense's technology aims to enable rapid, safe, and continuous ICP assessment without invasive procedures, primarily for triaging and managing traumatic brain injury (TBI) patients. The non-invasive approach could expand monitoring to milder TBI and other neurological conditions, addressing a significant unmet need. While the company has not disclosed funding or valuation, its technology has the potential to disrupt the standard of care in neurocritical care and emergency settings. CranioSense operates in a growing market for non-invasive ICP monitoring, driven by the high incidence of TBI and demand for safer diagnostic tools. The company's early-stage development means key milestones such as regulatory clearance and clinical validation are still ahead. If successful, IPASS could reduce complications, lower healthcare costs, and improve outcomes for millions of patients worldwide. However, the company faces technical challenges in ensuring accuracy compared to gold-standard invasive methods, as well as regulatory hurdles. CranioSense's progress will depend on securing funding, completing clinical studies, and navigating FDA approval. The technology holds promise but remains at a nascent stage with significant execution risk.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) submission for IPASS system60% success
• Q4 2026Publication of pivotal clinical trial results demonstrating ICP accuracy50% success
• Q1 2027Strategic partnership with a major hospital network or medical device distributor70% success